Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease

Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease

: In the acute myeloid leukemia (AML) setting, research has extensively investigated the existence and relevance of molecular biomarkers, in order to better tailor therapy with newly developed agents and hence improve outcomes and/or save the patient from poorly effective therapies. In particular, i...

Full description

Bibliographic Details
Main Authors:	Luca Maurillo, Renato Bassan, Nicola Cascavilla, Fabio Ciceri
Format:	Article
Language:	English
Published:	MDPI AG 2019-09-01
Series:	Cancers
Subjects:	Acute myeloid leukemia minimal residual disease tailored therapy
Online Access:	https://www.mdpi.com/2072-6694/11/10/1417

Similar Items

Angiogenesis and Minimal Residual Disease in Patients with Acute Myeloid Leukemia
by: Pardis Nematollahi, et al.
Published: (2020-04-01)

Predicting time to relapse in acute myeloid leukemia through stochastic modeling of minimal residual disease based on clonality data
by: Khanh N. Dinh, et al.
Published: (2021-09-01)

MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA OF ADULTS: DETERMINATION, PROGNOSTIC IMPACT AND CLINICAL APPLICATIONS.
by: Maria Ilaria Del Principe
Published: (2016-10-01)

'Childhood systemic mastocytosis associated with t (8; 21) (q22; q22) acute myeloid leukemia'
by: Nikhil Rabade, et al.
Published: (2016-01-01)

Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances
by: Cumbo C, et al.
Published: (2020-05-01)

Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?
by: Federico Mosna, et al.
Published: (2017-06-01)

Flow-Cytometric Monitoring of Minimal Residual Disease in Pediatric Patients With Acute Myeloid Leukemia: Recent Advances and Future Strategies
by: Barbara Buldini, et al.
Published: (2019-10-01)

Molecular monitoring of minimal residual disease in two patients with <it>MLL</it>-rearranged acute myeloid leukemia and haploidentical transplantation after relapse
by: Burmeister Thomas, et al.
Published: (2012-04-01)

CLINICAL ANALYSIS AND OPTIMIZATION OF POST-REMISSION THERAPY FOR ACUTE MYELOID LEUKEMIA PATIENTS WITH MINIMAL RESIDUAL DISEASE AS DETERMINED BY FLOW CYTOMETRY
by: Daichi Inoue, et al.
Published: (2010-08-01)

CLINICAL ANALYSIS AND OPTIMIZATION OF POST-REMISSION THERAPY FOR ACUTE MYELOID LEUKEMIA PATIENTS WITH MINIMAL RESIDUAL DISEASE AS DETERMINED BY FLOW CYTOMETRY
by: Hayato Maruoka, et al.
Published: (2010-05-01)

Minimal Residual Disease as a Predictive Factor for Relapse after Allogeneic Hematopoietic Stem Cell Transplant in Adult Patients with Acute Myeloid Leukemia in First and Second Complete Remission
by: Rada M. Grubovikj, et al.
Published: (2012-06-01)

Development of real-time quantitative polymerase chain reaction assays to track treatment response in retinoid resistant acute promyelocytic leukemia
by: Jelena V Jovanovic, et al.
Published: (2011-10-01)

Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia
by: Marisa J. L. Aitken, et al.
Published: (2021-09-01)

Minimal Residual Disease Detection in Pediatric Acute Lymphoblastic Leukemia
by: Miyoung Kim, et al.
Published: (2020-10-01)

Unsupervised Flow Cytometry Analysis Allows for an Accurate Identification of Minimal Residual Disease Assessment in Acute Myeloid Leukemia
by: Jean Philippe Vial, et al.
Published: (2021-02-01)

Prognostic Value of Genetic Alterations in Elderly Patients with Acute Myeloid Leukemia: A Single Institution Experience
by: Maël Heiblig, et al.
Published: (2019-04-01)

Is There Still a Role for Autologous Stem Cell Transplantation for the Treatment of Acute Myeloid Leukemia?
by: Felicetto Ferrara, et al.
Published: (2019-12-01)

PROGNOSTIC SIGNIFICANCE AND TREATMENT IMPLICATIONS OF MINIMAL RESIDUAL DISEASE STUDIES IN PHILADELPHIA-NEGATIVE ADULT ACUTE LYMPHOBLASTIC LEUKEMIA
by: Orietta Spinelli, et al.
Published: (2014-08-01)

Assessment of minimal residual disease in childhood acute lymphoblastic leukemia
by: Sonia K Parikh, et al.
Published: (2016-01-01)

Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia
by: Gregory W. Roloff, et al.
Published: (2017-09-01)

Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?
by: Justin Loke, et al.
Published: (2021-05-01)

Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment
by: Christina Rautenberg, et al.
Published: (2019-01-01)

In Silico Methods for the Identification of Diagnostic and Favorable Prognostic Markers in Acute Myeloid Leukemia
by: Hande Yılmaz, et al.
Published: (2021-09-01)

Escape From Treatment; the Different Faces of Leukemic Stem Cells and Therapy Resistance in Acute Myeloid Leukemia
by: Noortje van Gils, et al.
Published: (2021-05-01)

Pediatric acute lymphoblastic leukemia treatment protocols improvement: emphasis on minimal residual disease
by: M. A. Shervashidze, et al.
Published: (2020-10-01)

Detection of anti-Toxoplasma gondii antibodies in chronic myeloid leukemia and acute myeloid leukemia patients
by: Mohammad Javad Gharavi, et al.
Published: (2017-09-01)

Genetic Hierarchy of Acute Myeloid Leukemia: From Clonal Hematopoiesis to Molecular Residual Disease
by: Jean-Alain Martignoles, et al.
Published: (2018-12-01)

Measurable Residual Disease in Acute Myeloid Leukemia Using Flow Cytometry: A Review of Where We Are and Where We Are Going
by: Caroline Dix, et al.
Published: (2020-06-01)

Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia
by: Jennifer M. Yoest, et al.
Published: (2020-05-01)

Myeloid Sarcoma in an Eyelid That Developed during Chemotherapy for Acute Myeloid Leukemia
by: Hyera Kang, et al.
Published: (2016-01-01)

Anterior myeloid sarcoma revealing acute myeloid leukemia: Case report
by: H. Slimani, et al.
Published: (2016-07-01)

Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness
by: Raffaele Palmieri, et al.
Published: (2020-01-01)

Dendritic cell-based immunotherapy for myeloid leukemias
by: Christian Martijn Schürch, et al.
Published: (2013-12-01)

Flow cytometric minimal residual disease monitoring in children with acute lymphoblastic leukemia treated by regimens with reduced intensity
by: A. M. Popov, et al.
Published: (2015-12-01)

Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia
by: Aaron Kruse, et al.
Published: (2020-02-01)

Acute Myeloid Leukemia: analysis of epidemiological profile and survival rate
by: Mariana Cardoso de Lima, et al.
Published: (2016-05-01)

Evaluation of Minimal Residual Disease in Acute Myeloid Leukemia with NPM1 Marker
by: Nasrin Alizad Ghandforoush, et al.
Published: (2016-06-01)

Development of program therapy for patients with acute myeloid leukemia under the age of 60 years, based on the principles of differentiated effects
by: Elena N. Parovichnikova, et al.
Published: (2021-07-01)

Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia
by: G.A.P. Oliveira, et al.
Published: (2010-06-01)

Liver Involvement with Acute Myeloid Leukemia
by: Emily Mathews, et al.
Published: (2008-03-01)

Cannot write session to /tmp/vufind_sessions/sess_5nehomekthom91mmje5lo027nt